Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biovaxys Technology Corp (BIOV.CN)

Biovaxys Technology Corp (BIOV.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 17,285
  • Shares Outstanding, K 246,926
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,687 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 2.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $0.00 on 07/10/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0500 +30.00%
on 10/22/24
0.0800 -18.75%
on 11/05/24
+0.0150 (+30.00%)
since 10/18/24
3-Month
0.0450 +44.44%
on 10/18/24
0.0800 -18.75%
on 11/05/24
+0.0250 (+62.50%)
since 08/16/24
52-Week
0.0100 +550.00%
on 12/14/23
0.1000 -35.00%
on 02/28/24
+0.0400 (+160.00%)
since 10/06/23

Most Recent Stories

More News
Stocks in play: BioVaxys Technology Corp

Announces it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium ...

BIOV.CN : 0.0650 (-7.14%)
BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and...

BVAXF : 0.0494 (unch)
BIOV.CN : 0.0650 (-7.14%)
Stocks in play: BioVaxys Technology Corp

Announces studies showing that its novel immune educating delivery platform, DPXâ„¢, recruits and activates ...

BIOV.CN : 0.0650 (-7.14%)
BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights studies showing that its novel immune...

BVAXF : 0.0494 (unch)
BIOV.CN : 0.0650 (-7.14%)
Stocks in play: BioVaxys Technology Corp

Announces that Chief Executive Officer James Passin has been invited to present live at the Emerging ...

BIOV.CN : 0.0650 (-7.14%)
BioVaxys to Present at the Emerging Growth Conference on October 30th, 2024

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of...

BVAXF : 0.0494 (unch)
BIOV.CN : 0.0650 (-7.14%)
BIOVAXYS PROVIDES PRIVATE PLACEMENT UPDATES

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that, further to its news releases regarding its previously...

BIOV.CN : 0.0650 (-7.14%)
Stocks in play: BioVaxys Technology Corp

Announces it has engaged Rajkannan Rajagopalan, PhD, as Advisor for development and production of the ...

BIOV.CN : 0.0650 (-7.14%)
BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Rajkannan Rajagopalan, PhD,...

BVAXF : 0.0494 (unch)
BIOV.CN : 0.0650 (-7.14%)
BIOVAXYS ANNOUNCES CLOSING OF FIFTH TRANCHE OF PRIVATE PLACEMENT

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fifth tranche (the "Fifth...

BIOV.CN : 0.0650 (-7.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization,...

See More

Key Turning Points

3rd Resistance Point 0.0800
2nd Resistance Point 0.0750
1st Resistance Point 0.0725
Last Price 0.0650
1st Support Level 0.0650
2nd Support Level 0.0600
3rd Support Level 0.0575

See More

52-Week High 0.1000
Fibonacci 61.8% 0.0656
Last Price 0.0650
Fibonacci 50% 0.0550
Fibonacci 38.2% 0.0444
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar